English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 15 December 2020, 09:00 HKT/SGT
Share:
    

Source: Azooka Labs
Azooka Labs unveils Safe MTM to Store COVID-19 Samples at Room Temperature for up to a week
Molecular Transport Medium at the price of VTM

BANGALORE, INDIA, Dec 15, 2020 - (ACN Newswire) - Azooka Labs, a leading safe fluorophore company with specialization in Molecular Biology products, reveals its first range of novel COVID-19 diagnostics products. RNA Wrapr is a molecular transport medium for COVID-19 sample collection, developed as part of the COVID-19 response team from Indian Institute of Science.

Molecular Transport Media that inactivates the Coronavirus immediately. Not only that! Azooka's RNA Wrapr does not require dry ice for storage and can be processed until a week. A storage medium for COVID-19 that is safe, easy to use and affordable. (RNA Wrapr comes in 3ml or 10ml vials with Fluccoluated Nylon Nasal Swabs. Price starts at INR 99 per vial.)

RNA Wrapr inactivates the virus immediately only preserving DNA/RNA content required for RT-PCR tests. The sample tubes can be stored up to 7 days in Room Temperature and transported without dry ice or gel packs. RNA Wrapr is safe to handle even during unexpected accidental spillage or handling errors. Developing countries can collect samples in centers without BSL2 or BSL3 certifications.

Azooka's RNA Wrapr is priced at INR 99 in India, aligned with the price of one litre of petrol, to help the diagnostic centers upgrade from VTM to MTM. Azooka plans to enter the APAC market through partners with $9 and $6 pricing plans per test.

"Azooka has actively been a part of the fight against COVID by developing PCR and RT PCR kits with support from Dept of Biotechnology and Elevate Karnataka even before the pandemic hit us," quoted Alex D Paul, CEO, Azooka Labs. He further added, "MTM has ensured safety and security of COVID-19 samples to be stored at Room Temperature for up to seven days".

"Azooka is the only startup from India working to replace Carcinogenic and Mutagenic SYBR dyes widely used in RUO and Diagnostics reagents. Safety and cost savings needed for COVID crisis management today are the highlights of Azooka's MTM," says Dr. C V Natraj, former SVP, Corporate Research, Unilever plc.

"Azooka is striving to provide a safer molecular grade transport medium that is at sub Rs. 100. We are appealing to a segment of users, who care about the safety of their frontline health care workers," stated Dr. Fatima Benazir, Co-founder & CSO, Azooka Labs.

About Azooka Labs
Azooka is a patented fluorophore company focused on developing safe biotech consumables at a price affordable for all countries across the globe. Azooka's first diagnostics product RNA Wrapr- molecular transport medium, is approved by ICMR and certified by CE. Azooka is an IISc invested startup based in Bengaluru with R&D unit at the Indian Institute of Science and manufacturing facility in Peenya Industrial Area, Karnataka.

Azooka was recently awarded the 'Best Women-Led Enterprise' at StartUp India 2020. Azooka is open for licensing and partnerships worldwide. Governments and Health Organizations can directly contact Azooka for COVID-19 Crisis Management. For more information visit: http://azooka.life/ and for the prices visit: https://azooka.life/rna-wrapr-molecular-transport-medium/

Media Contact:
Alex D Paul, CEO
+91-9108424562
alx@azooka.life

Topic: Press release summary
Source: Azooka Labs

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans  
Apr 26, 2024 23:00 HKT/SGT
Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family  
Apr 26, 2024 22:25 HKT/SGT
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences  
Apr 26, 2024 21:10 HKT/SGT
TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023  
Apr 26, 2024 18:26 HKT/SGT
UK advertising reports GBP36.6bn spend in 2023  
Apr 26, 2024 17:30 HKT/SGT
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine  
Apr 26, 2024 15:36 HKT/SGT
Edvantage Group Announces FY2024 Interim Results  
Apr 26, 2024 13:43 HKT/SGT
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project  
Apr 26, 2024 13:27 HKT/SGT
Imexpharm Corporation Hosts Shareholders, Analysts and Potential Investors at its 2024 Annual General Meeting  
Apr 26, 2024 13:16 HKT/SGT
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan  
Friday, April 26, 2024 9:00:00 AM
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575